Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-directed individualized fluoropyrimidine dosing for DPD deficiency
2014-005064-15Phase 4Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of capecitabine and fluorouracil in cancer, colorectal cancer (CRC), gastric cancer (GC) and 1 more (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of severe treatment-related toxicity. Started Dec 2014; status: completed.
02
Drugs
capecitabinefluorouracil
03
Conditions
cancercolorectal cancer (CRC)gastric cancer (GC)breast cancer
Beyond the preview
Go deeper on 2014-005064-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005064-15.